Efficacy And Safety Study Of Atorvastatin Versus Simvastatin In Type 2 Diabetic Subjects With Hypercholesterolemia

NCT00141141 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

383

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypercholesterolemia

Interventions

DRUG: Atorvastatin
DRUG: Simvastatin

Sponsor

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.